Bone-Targeted Calcium Phosphate-Polymer Hybrid Nanoparticle Co-Deliver Zoledronate and Docetaxel to Treat Bone Metastasis of Prostate Cancer

Qian Yang,Dao-Zhou Liu,Miao Liu,Qi-Feng Ji,Qi-Bing Mei,Ying Cheng,Si-Yuan Zhou,Dao-zhou Liu,Qi-feng Ji,Qi-bing Mei,Si-yuan Zhou
DOI: https://doi.org/10.1016/j.xphs.2020.11.005
IF: 3.8
2021-02-01
Journal of Pharmaceutical Sciences
Abstract:<p>Prostate cancer is the most common malignant tumor with bone metastasis, and there is still no ideal treatment for bone metastasis of prostate cancer. In this study, a pH and GSH dual sensitive calcium phosphate-polymer hybrid nanoparticle (/HP) was prepared to co-deliver zoledronate (ZOL) and docetaxel (DTX) to treat bone metastasis of prostate cancer. /HP exhibited high bone binding affinity and released more DTX and ZOL in acidic and high GSH concentration environment. A large amount of /HP was uptaken by PC-3 cell in acidic medium than that in neutral medium. /HP obviously reduced PC-3 cell proliferation and bone lesion in <em>in-vitro</em> 3D model of bone metastases of prostate cancer. Besides, /HP also exhibited stronger anti bone metastases of prostate cancer activity <em>in vivo</em> as compared with the same dose of DTX+ZOL, which resulted from the co-delivery of DTX and ZOL to bone metastases of prostate cancer by /HP and the synergistic effects of DTX and ZOL. /HP has great potential in the treatment of bone metastases of prostate cancer.</p>
pharmacology & pharmacy,chemistry, medicinal, multidisciplinary
What problem does this paper attempt to address?